Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025

Vinge has advised Stirling Square Capital Partners (“SSCP”) in connection with the sale of part of its holding in Infobric to KKR

Pursuant to the transaction, KKR has become a significant owner, while SSCP will remain the largest owner.
October 15, 2025

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 1 billion

Vinge has advised ABG Sundal Collier in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 1 billion, and parallel written procedure to increase the bond framework to SEK 2 billion.
October 15, 2025